The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity
The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with ob...
Ausführliche Beschreibung
Autor*in: |
Antonella Mosca [verfasserIn] Luca Della Volpe [verfasserIn] Anna Alisi [verfasserIn] Nadia Panera [verfasserIn] Giuseppe Maggiore [verfasserIn] Andrea Vania [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2022 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Metabolites - MDPI AG, 2012, 12(2022), 12, p 1221 |
---|---|
Übergeordnetes Werk: |
volume:12 ; year:2022 ; number:12, p 1221 |
Links: |
---|
DOI / URN: |
10.3390/metabo12121221 |
---|
Katalog-ID: |
DOAJ083029044 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ083029044 | ||
003 | DE-627 | ||
005 | 20240414150511.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230311s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/metabo12121221 |2 doi | |
035 | |a (DE-627)DOAJ083029044 | ||
035 | |a (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a QR1-502 | |
100 | 0 | |a Antonella Mosca |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. | ||
650 | 4 | |a GH | |
650 | 4 | |a nonalcoholic fatty liver disease | |
650 | 4 | |a fibrosis | |
650 | 4 | |a IGF1 | |
653 | 0 | |a Microbiology | |
700 | 0 | |a Luca Della Volpe |e verfasserin |4 aut | |
700 | 0 | |a Anna Alisi |e verfasserin |4 aut | |
700 | 0 | |a Nadia Panera |e verfasserin |4 aut | |
700 | 0 | |a Giuseppe Maggiore |e verfasserin |4 aut | |
700 | 0 | |a Andrea Vania |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Metabolites |d MDPI AG, 2012 |g 12(2022), 12, p 1221 |w (DE-627)718627164 |w (DE-600)2662251-8 |x 22181989 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2022 |g number:12, p 1221 |
856 | 4 | 0 | |u https://doi.org/10.3390/metabo12121221 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf |z kostenfrei |
856 | 4 | 0 | |u https://www.mdpi.com/2218-1989/12/12/1221 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2218-1989 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 12 |j 2022 |e 12, p 1221 |
author_variant |
a m am l d v ldv a a aa n p np g m gm a v av |
---|---|
matchkey_str |
article:22181989:2022----::hrlotehg1xsnhdvlpetfalipdar |
hierarchy_sort_str |
2022 |
callnumber-subject-code |
QR |
publishDate |
2022 |
allfields |
10.3390/metabo12121221 doi (DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf DE-627 ger DE-627 rakwb eng QR1-502 Antonella Mosca verfasserin aut The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology Luca Della Volpe verfasserin aut Anna Alisi verfasserin aut Nadia Panera verfasserin aut Giuseppe Maggiore verfasserin aut Andrea Vania verfasserin aut In Metabolites MDPI AG, 2012 12(2022), 12, p 1221 (DE-627)718627164 (DE-600)2662251-8 22181989 nnns volume:12 year:2022 number:12, p 1221 https://doi.org/10.3390/metabo12121221 kostenfrei https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf kostenfrei https://www.mdpi.com/2218-1989/12/12/1221 kostenfrei https://doaj.org/toc/2218-1989 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 12, p 1221 |
spelling |
10.3390/metabo12121221 doi (DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf DE-627 ger DE-627 rakwb eng QR1-502 Antonella Mosca verfasserin aut The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology Luca Della Volpe verfasserin aut Anna Alisi verfasserin aut Nadia Panera verfasserin aut Giuseppe Maggiore verfasserin aut Andrea Vania verfasserin aut In Metabolites MDPI AG, 2012 12(2022), 12, p 1221 (DE-627)718627164 (DE-600)2662251-8 22181989 nnns volume:12 year:2022 number:12, p 1221 https://doi.org/10.3390/metabo12121221 kostenfrei https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf kostenfrei https://www.mdpi.com/2218-1989/12/12/1221 kostenfrei https://doaj.org/toc/2218-1989 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 12, p 1221 |
allfields_unstemmed |
10.3390/metabo12121221 doi (DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf DE-627 ger DE-627 rakwb eng QR1-502 Antonella Mosca verfasserin aut The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology Luca Della Volpe verfasserin aut Anna Alisi verfasserin aut Nadia Panera verfasserin aut Giuseppe Maggiore verfasserin aut Andrea Vania verfasserin aut In Metabolites MDPI AG, 2012 12(2022), 12, p 1221 (DE-627)718627164 (DE-600)2662251-8 22181989 nnns volume:12 year:2022 number:12, p 1221 https://doi.org/10.3390/metabo12121221 kostenfrei https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf kostenfrei https://www.mdpi.com/2218-1989/12/12/1221 kostenfrei https://doaj.org/toc/2218-1989 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 12, p 1221 |
allfieldsGer |
10.3390/metabo12121221 doi (DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf DE-627 ger DE-627 rakwb eng QR1-502 Antonella Mosca verfasserin aut The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology Luca Della Volpe verfasserin aut Anna Alisi verfasserin aut Nadia Panera verfasserin aut Giuseppe Maggiore verfasserin aut Andrea Vania verfasserin aut In Metabolites MDPI AG, 2012 12(2022), 12, p 1221 (DE-627)718627164 (DE-600)2662251-8 22181989 nnns volume:12 year:2022 number:12, p 1221 https://doi.org/10.3390/metabo12121221 kostenfrei https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf kostenfrei https://www.mdpi.com/2218-1989/12/12/1221 kostenfrei https://doaj.org/toc/2218-1989 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 12, p 1221 |
allfieldsSound |
10.3390/metabo12121221 doi (DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf DE-627 ger DE-627 rakwb eng QR1-502 Antonella Mosca verfasserin aut The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology Luca Della Volpe verfasserin aut Anna Alisi verfasserin aut Nadia Panera verfasserin aut Giuseppe Maggiore verfasserin aut Andrea Vania verfasserin aut In Metabolites MDPI AG, 2012 12(2022), 12, p 1221 (DE-627)718627164 (DE-600)2662251-8 22181989 nnns volume:12 year:2022 number:12, p 1221 https://doi.org/10.3390/metabo12121221 kostenfrei https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf kostenfrei https://www.mdpi.com/2218-1989/12/12/1221 kostenfrei https://doaj.org/toc/2218-1989 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 12, p 1221 |
language |
English |
source |
In Metabolites 12(2022), 12, p 1221 volume:12 year:2022 number:12, p 1221 |
sourceStr |
In Metabolites 12(2022), 12, p 1221 volume:12 year:2022 number:12, p 1221 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology |
isfreeaccess_bool |
true |
container_title |
Metabolites |
authorswithroles_txt_mv |
Antonella Mosca @@aut@@ Luca Della Volpe @@aut@@ Anna Alisi @@aut@@ Nadia Panera @@aut@@ Giuseppe Maggiore @@aut@@ Andrea Vania @@aut@@ |
publishDateDaySort_date |
2022-01-01T00:00:00Z |
hierarchy_top_id |
718627164 |
id |
DOAJ083029044 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ083029044</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414150511.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/metabo12121221</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ083029044</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR1-502</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antonella Mosca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">GH</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nonalcoholic fatty liver disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fibrosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IGF1</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Microbiology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luca Della Volpe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Alisi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nadia Panera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Maggiore</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Vania</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Metabolites</subfield><subfield code="d">MDPI AG, 2012</subfield><subfield code="g">12(2022), 12, p 1221</subfield><subfield code="w">(DE-627)718627164</subfield><subfield code="w">(DE-600)2662251-8</subfield><subfield code="x">22181989</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:12, p 1221</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/metabo12121221</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2218-1989/12/12/1221</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2218-1989</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2022</subfield><subfield code="e">12, p 1221</subfield></datafield></record></collection>
|
callnumber-first |
Q - Science |
author |
Antonella Mosca |
spellingShingle |
Antonella Mosca misc QR1-502 misc GH misc nonalcoholic fatty liver disease misc fibrosis misc IGF1 misc Microbiology The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity |
authorStr |
Antonella Mosca |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)718627164 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
QR1-502 |
illustrated |
Not Illustrated |
issn |
22181989 |
topic_title |
QR1-502 The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity GH nonalcoholic fatty liver disease fibrosis IGF1 |
topic |
misc QR1-502 misc GH misc nonalcoholic fatty liver disease misc fibrosis misc IGF1 misc Microbiology |
topic_unstemmed |
misc QR1-502 misc GH misc nonalcoholic fatty liver disease misc fibrosis misc IGF1 misc Microbiology |
topic_browse |
misc QR1-502 misc GH misc nonalcoholic fatty liver disease misc fibrosis misc IGF1 misc Microbiology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Metabolites |
hierarchy_parent_id |
718627164 |
hierarchy_top_title |
Metabolites |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)718627164 (DE-600)2662251-8 |
title |
The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity |
ctrlnum |
(DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf |
title_full |
The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity |
author_sort |
Antonella Mosca |
journal |
Metabolites |
journalStr |
Metabolites |
callnumber-first-code |
Q |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2022 |
contenttype_str_mv |
txt |
author_browse |
Antonella Mosca Luca Della Volpe Anna Alisi Nadia Panera Giuseppe Maggiore Andrea Vania |
container_volume |
12 |
class |
QR1-502 |
format_se |
Elektronische Aufsätze |
author-letter |
Antonella Mosca |
doi_str_mv |
10.3390/metabo12121221 |
author2-role |
verfasserin |
title_sort |
role of the gh/igf1 axis on the development of mafld in pediatric patients with obesity |
callnumber |
QR1-502 |
title_auth |
The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity |
abstract |
The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. |
abstractGer |
The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. |
abstract_unstemmed |
The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
12, p 1221 |
title_short |
The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity |
url |
https://doi.org/10.3390/metabo12121221 https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf https://www.mdpi.com/2218-1989/12/12/1221 https://doaj.org/toc/2218-1989 |
remote_bool |
true |
author2 |
Luca Della Volpe Anna Alisi Nadia Panera Giuseppe Maggiore Andrea Vania |
author2Str |
Luca Della Volpe Anna Alisi Nadia Panera Giuseppe Maggiore Andrea Vania |
ppnlink |
718627164 |
callnumber-subject |
QR - Microbiology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3390/metabo12121221 |
callnumber-a |
QR1-502 |
up_date |
2024-07-03T15:09:16.586Z |
_version_ |
1803571016856764416 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ083029044</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414150511.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/metabo12121221</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ083029044</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR1-502</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antonella Mosca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">GH</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nonalcoholic fatty liver disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fibrosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IGF1</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Microbiology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luca Della Volpe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Alisi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nadia Panera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Maggiore</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Vania</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Metabolites</subfield><subfield code="d">MDPI AG, 2012</subfield><subfield code="g">12(2022), 12, p 1221</subfield><subfield code="w">(DE-627)718627164</subfield><subfield code="w">(DE-600)2662251-8</subfield><subfield code="x">22181989</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:12, p 1221</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/metabo12121221</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2218-1989/12/12/1221</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2218-1989</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2022</subfield><subfield code="e">12, p 1221</subfield></datafield></record></collection>
|
score |
7.399047 |